Myeloproliferative neoplasm epidemiology and demographics
|
Myeloproliferative Neoplasm Microchapters |
|
Differentiating myeloproliferative neoplasm from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Myeloproliferative neoplasm epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Myeloproliferative neoplasm epidemiology and demographics |
|
FDA on Myeloproliferative neoplasm epidemiology and demographics |
|
on Myeloproliferative neoplasm epidemiology and demographics |
|
Myeloproliferative neoplasm epidemiology and demographics in the news |
|
Blogs on Myeloproliferative neoplasm epidemiology and demographics |
|
Directions to Hospitals Treating Myeloproliferative neoplasm |
|
Risk calculators and risk factors for Myeloproliferative neoplasm epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2] Shyam Patel [3]
Overview
The incidence of myeloproliferative neoplasm is approximately 2.3-7.8 per 100,000 individuals worldwide.[1] [2]
Epidemiology and Demographics
Incidence
The incidence of myeloproliferative neoplasm is approximately 7.8 per 100,000 individuals worldwide.[1] There are varying incidences for the different subtypes of myeloproliferative neoplasm. The incidence of polycythemia vera is 2 per 100,000 individuals.[3]
Age
The prevalence of myeloproliferative neoplasm increases with age.[4]
Gender
Males are more commonly affected with myeloproliferative neoplasm than females.[4] However, females are more likely to be affected by the abdominal symptoms of myeloproliferative neoplasm.[5] Females are also more likely to develop thrombocytopenia than males.[5]. Females have a shorter disease duration.
Race
The prevalence of myeloproliferative neoplasm does not vary by race.[4]
References
- ↑ 1.0 1.1 Centers for Disease Control and Prevention. WTC Health Program.Myeloid Malignancieshttp://www.cdc.gov/wtc/pdfs/WTCHP_PP_MyeloidMalignancies_02012014.pdf
- ↑ Kristinsson SY, Landgren O, Samuelsson J, Björkholm M, Goldin LR (2010). "Autoimmunity and the risk of myeloproliferative neoplasms". Haematologica. 95 (7): 1216–20. doi:10.3324/haematol.2009.020412. PMC 2895049. PMID 20053870.
- ↑ Kiladjian JJ, Winton EF, Talpaz M, Verstovsek S (2015). "Ruxolitinib for the treatment of patients with polycythemia vera". Expert Rev Hematol. 8 (4): 391–401. doi:10.1586/17474086.2015.1045869. PMC 4627585. PMID 25980454.
- ↑ 4.0 4.1 4.2 Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA; et al. (2008). "Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs". Blood. 112 (1): 45–52. doi:10.1182/blood-2008-01-134858. PMID 18443215.
- ↑ 5.0 5.1 Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S; et al. (2017). "Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group". Haematologica. 102 (1): 85–93. doi:10.3324/haematol.2016.149559. PMC 5210236. PMID 27540137.